产经

订阅

MedSci主页 / 所有栏目 / 产经

阿斯利康11.5亿美元布局RNA修饰蛋白靶向疗法，强化肿瘤领域布局

2020-06-09 黎元 医药魔方Pro

阿斯利康肿瘤领域
关注

6月4日，阿斯利康宣布将向Accent Therapeutics支付5500万美元的预付款来获取Accent在

6月4日，阿斯利康宣布将向Accent Therapeutics支付5500万美元的预付款来获取Accent在RNA修饰蛋白（RNA-modifying protein）生物学领域的专有药物发现技术。
Accent是RNA修饰蛋白靶向疗法生物学、靶点识别和药物发现领域的领导者。阿斯利康希望通过靶向RNA修饰酶和其它癌症相关蛋白的疗法来增强其癌症研发投资组合。
 
如果与阿斯利康的合作取得成功，Accent还有可能获得总计约11亿美元的里程金和来自上市产品的销售版税。
 
根据协议，Accent将负责进行临床前项目的研发直到I期临床试验。一旦评估完成，阿斯利康将接手，进行进一步的临床开发，以及药物获批后的商业化。此外，阿斯利康还具有两项以上临床前开发项目的许可权。
 
图片来源：Accent Therapeutics官网
  
Accent成立于2018年，总部位于马萨诸塞州，此前已完成4000万美元A轮融资和6300万美元的B轮融资。目前公司已建立了小分子疗法的管线，其中两个项目靶向METTL3和ADAR1这两种在某些癌症中发挥作用的酶。
 
RNA修饰的生物学领域相对较新。能够抑制癌症相关酶和其它可修饰RNA的蛋白质的小分子药物，旨在破坏癌细胞生长对这些酶的依赖。
 
RNA修饰蛋白及其作用过程（图片来源：Accent Therapeutics官网）
  
“RNA修饰蛋白抑制剂很有前途，这是阿斯利康一个势在必行的探索领域。”阿斯利康肿瘤研发部门执行副总裁José Baselga说。
  
Accent CEO Shakti Narayan博士补充道：“这项合作将使我们能够迅速推进并实现RNA修饰蛋白项目丰富的治疗潜力。阿斯利康大量的癌症专业知识和资源与Accent丰富的RNA修饰蛋白疗法管线将为患者带来可能改变生命的新药物。“
参考资料：
1# Accent, AstraZeneca Ink Cancer Drug Dealto Block RNA-Modifying Proteins（来源：Xconomy）
2# AstraZeneca to discover and develop novel therapies targeting RNA-modifying proteins in oncology collaboration with Accent Therapeutics（来源：AstraZeneca官网）

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057470, encodeId=583c205e470c6, content=<a href='/topic/show?id=a7d3155507b' target=_blank style='color:#2F92EE;'>#RNA修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15550, encryptionId=a7d3155507b, topicName=RNA修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Feb 24 05:06:53 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069879, encodeId=f7fb20698e938, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Feb 09 16:06:53 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378549, encodeId=d54513e8549f3, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Thu Jun 11 13:06:53 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569389, encodeId=722415693891d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Jun 11 13:06:53 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601946, encodeId=c91f60194683, content=有望实现RNA修饰蛋白项目丰富的治疗潜力, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Jun 10 09:50:48 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601926, encodeId=3174601926ea, content=AZ厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 09 23:08:26 CST 2020, time=2020-06-09, status=1, ipAttribution=)]
    2021-02-24 drj2003

    #RNA修饰#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2057470, encodeId=583c205e470c6, content=<a href='/topic/show?id=a7d3155507b' target=_blank style='color:#2F92EE;'>#RNA修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15550, encryptionId=a7d3155507b, topicName=RNA修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Feb 24 05:06:53 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069879, encodeId=f7fb20698e938, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Feb 09 16:06:53 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378549, encodeId=d54513e8549f3, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Thu Jun 11 13:06:53 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569389, encodeId=722415693891d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Jun 11 13:06:53 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601946, encodeId=c91f60194683, content=有望实现RNA修饰蛋白项目丰富的治疗潜力, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Jun 10 09:50:48 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601926, encodeId=3174601926ea, content=AZ厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 09 23:08:26 CST 2020, time=2020-06-09, status=1, ipAttribution=)]
    2021-02-09 vividelife

    #肿瘤领域#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2057470, encodeId=583c205e470c6, content=<a href='/topic/show?id=a7d3155507b' target=_blank style='color:#2F92EE;'>#RNA修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15550, encryptionId=a7d3155507b, topicName=RNA修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Feb 24 05:06:53 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069879, encodeId=f7fb20698e938, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Feb 09 16:06:53 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378549, encodeId=d54513e8549f3, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Thu Jun 11 13:06:53 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569389, encodeId=722415693891d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Jun 11 13:06:53 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601946, encodeId=c91f60194683, content=有望实现RNA修饰蛋白项目丰富的治疗潜力, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Jun 10 09:50:48 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601926, encodeId=3174601926ea, content=AZ厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 09 23:08:26 CST 2020, time=2020-06-09, status=1, ipAttribution=)]
    2020-06-11 yanghan

    #靶向疗法#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2057470, encodeId=583c205e470c6, content=<a href='/topic/show?id=a7d3155507b' target=_blank style='color:#2F92EE;'>#RNA修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15550, encryptionId=a7d3155507b, topicName=RNA修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Feb 24 05:06:53 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069879, encodeId=f7fb20698e938, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Feb 09 16:06:53 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378549, encodeId=d54513e8549f3, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Thu Jun 11 13:06:53 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569389, encodeId=722415693891d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Jun 11 13:06:53 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601946, encodeId=c91f60194683, content=有望实现RNA修饰蛋白项目丰富的治疗潜力, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Jun 10 09:50:48 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601926, encodeId=3174601926ea, content=AZ厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 09 23:08:26 CST 2020, time=2020-06-09, status=1, ipAttribution=)]
    2020-06-11 zhangyxzsh

    #修饰#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2057470, encodeId=583c205e470c6, content=<a href='/topic/show?id=a7d3155507b' target=_blank style='color:#2F92EE;'>#RNA修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15550, encryptionId=a7d3155507b, topicName=RNA修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Feb 24 05:06:53 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069879, encodeId=f7fb20698e938, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Feb 09 16:06:53 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378549, encodeId=d54513e8549f3, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Thu Jun 11 13:06:53 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569389, encodeId=722415693891d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Jun 11 13:06:53 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601946, encodeId=c91f60194683, content=有望实现RNA修饰蛋白项目丰富的治疗潜力, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Jun 10 09:50:48 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601926, encodeId=3174601926ea, content=AZ厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 09 23:08:26 CST 2020, time=2020-06-09, status=1, ipAttribution=)]
    2020-06-10 神盾医疗局局长Jack

    有望实现RNA修饰蛋白项目丰富的治疗潜力

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2057470, encodeId=583c205e470c6, content=<a href='/topic/show?id=a7d3155507b' target=_blank style='color:#2F92EE;'>#RNA修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15550, encryptionId=a7d3155507b, topicName=RNA修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Feb 24 05:06:53 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069879, encodeId=f7fb20698e938, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Feb 09 16:06:53 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378549, encodeId=d54513e8549f3, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Thu Jun 11 13:06:53 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569389, encodeId=722415693891d, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Jun 11 13:06:53 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601946, encodeId=c91f60194683, content=有望实现RNA修饰蛋白项目丰富的治疗潜力, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Jun 10 09:50:48 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601926, encodeId=3174601926ea, content=AZ厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 09 23:08:26 CST 2020, time=2020-06-09, status=1, ipAttribution=)]
    2020-06-09 lovetcm

    AZ厉害

    0

相关资讯

阿斯利康的ADC药物在治疗晚期乳腺癌的II期临床中，疾病控制率达97.3%

阿斯利康（AstraZeneca）和第一三共（Daiichi Sankyo）提供了新的中期数据，这些数据显示接受靶向HER2的抗体药物偶联物（ADC）trastuzumab（曲妥珠单抗）-deruxtecan（DS-8201）治疗的晚期乳腺癌患者具有"临床意义"的改善。

阿斯利康和默克的PARP抑制剂Lynparza获FDA批准,用作晚期胰腺癌的维持治疗

阿斯利康和默克的PARP抑制剂Lynparza已获得FDA的批准，用作BRCA突变、经铂类化学疗法治疗后尚未进展的晚期胰腺癌（一种众所周知的难以治疗的癌症）的维持疗法。

阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查

阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga已获得美国FDA的优先审查，预计将在2020年第二季度获得批准。

2020 Q1各大药企收入排名，强生，罗氏，诺华，默沙东，辉瑞，礼来，阿斯利康......

4月份，强生，礼来，GSK，辉瑞、诺华、默沙东相继发布了2020年第一季度财报。在疫情的笼罩之下，今年注定是不平凡的一年。而对于跨国药企而言，其开年业绩就上演了“王座更迭”的戏

阿斯利康中国2019年同比强劲增长35%​！

GBI获悉，近日，英国制药巨头阿斯利康公布了2019年全年业绩，总收入243.84亿美元，同比增长13%（按固定汇率计算，下同），产品销售收入达235.7亿美元，同比增长15%，核心营业利润增长13％至64.4亿美元。   报告期内，中国市场收入48.80亿美元，同比增长35%，约占阿斯利康全球总收入的21%；第四季度收入同比增长28％至11.89亿美元。值得一提的是，新上市

2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期

阿斯利康的BTK抑制剂Calquence在一项III期试验中结果显示了该药物对慢性淋巴细胞性白血病（CLL）患者无进展生存期（PFS）的影响。